| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$8 |
$4.0m Non-Dilutionary Funding
|
27 Feb 2025 4:06PM |
$0.007 |
$0.004 |
fallen by
38.46%
|
|
CHM - Price-sensitive ASX Announcement
Full Release
Key Points
- Chimeric Therapeutics received A$4.0 million in non-dilutionary funding.
- Funding was provided by a US-based philanthropic family office.
- The funds are for the development of CHM CDH17 CAR-T therapy.
- CHM CDH17 targets CDH17, a marker associated with poor prognosis in gastrointestinal cancers.
- The therapy is in a Phase 1/2 clinical trial for advanced colorectal, gastric, and neuroendocrine cancers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oohmedia Limited (OML) ORDINARY FULLY PAID |
Communication Services |
$937 |
Becoming a substantial holder
|
27 Feb 2025 4:02PM |
$1.570 |
$1.740 |
risen by
10.83%
|
|
| RooLife Group Ltd (RLG) ORDINARY FULLY PAID |
Communication Services |
$8 |
Appendix 4D and Half Yearly Financial Statements
|
27 Feb 2025 3:57PM |
$0.004 |
$0.005 |
risen by
25%
|
|
RLG - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported revenue of $2,603,795 for the half-year ended 31 December 2024.
- Net loss of $949,742, slightly higher than the previous loss of $946,375.
- Focus on high-margin products to improve profitability.
- Strategic partnerships established in India for product distribution.
- Operational expenses reduced by 17% compared to the previous half-year.
- Company is enhancing its own brand portfolio including health and wellness products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metal Hawk Limited (MHK) ORDINARY FULLY PAID |
Materials |
$54 |
Change in substantial holding
|
27 Feb 2025 3:56PM |
$0.333 |
$0.440 |
risen by
32.33%
|
|
| Pantoro Gold Limited (PNR) ORDINARY FULLY PAID |
Materials |
$1,336 |
Notice under section 708A(5)(e) of the Corporations Act 2001
|
27 Feb 2025 3:47PM |
$0.140 |
$3.400 |
risen by
2,328.57%
|
|
| Pantoro Gold Limited (PNR) ORDINARY FULLY PAID |
Materials |
$1,336 |
Application for quotation of securities - PNR
|
27 Feb 2025 3:46PM |
$0.140 |
$3.400 |
risen by
2,328.57%
|
|
| Pantoro Gold Limited (PNR) ORDINARY FULLY PAID |
Materials |
$1,336 |
Conversion of Portion of Convertible Loan
|
27 Feb 2025 3:43PM |
$0.140 |
$3.400 |
risen by
2,328.57%
|
|
| Domain Holdings Australia Limited (DHG) ORDINARY FULLY PAID |
Communication Services |
$2,754 |
Initial Director's Interest Notice-Peter Tonagh
|
27 Feb 2025 3:37PM |
$4.360 |
$4.360 |
fallen by
0%
|
|
| Renu Energy Limited (RNE) ORDINARY FULLY PAID |
Utilities |
$0 |
Proposed issue of securities - RNE
|
27 Feb 2025 3:35PM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| TMK Energy Limited (TMK) ORDINARY FULLY PAID |
Energy |
$31 |
Proposed issue of securities - TMK
|
27 Feb 2025 3:32PM |
$0.004 |
$0.003 |
fallen by
14.29%
|
|
| NT Minerals Limited (NTM) ORDINARY FULLY PAID |
Materials |
$2 |
Review Highlights Fe Potential Within Woolbung BIF - Updated
|
27 Feb 2025 3:31PM |
$0.003 |
$0.002 |
fallen by
33.33%
|
|
| TMK Energy Limited (TMK) ORDINARY FULLY PAID |
Energy |
$31 |
Disclosure Document
|
27 Feb 2025 3:30PM |
$0.004 |
$0.003 |
fallen by
14.29%
|
|
| Thrive Tribe Technologies Limited (1TT) ORDINARY FULLY PAID |
Information Technology |
$2 |
Appendix 4D and Half Year Report for 31 Dec 2024
|
27 Feb 2025 3:22PM |
$0.003 |
$0.001 |
fallen by
60%
|
|
1TT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue down 61.3% to $65,779.
- Loss for the half-year increased by 11.2% to $1,241,844.
- No dividends paid during the current or previous financial period.
- Daily Food Brand Pty Ltd placed into administration.
- Company rebranded Kumu platform to MyTribe.
- Cash reserves of $666,112 as of 31 December 2024.
- Strategic review undertaken for operational improvements.
- Jade Spooner appointed as Group CEO on 21 January 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Spectur Limited (SP3) ORDINARY FULLY PAID |
Information Technology |
$4 |
H1 FY25 Financial Statements and Appendix 4D
|
27 Feb 2025 3:20PM |
$0.012 |
$0.013 |
risen by
8.33%
|
|
SP3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Spectur achieved record revenue of $4.464 million for H1 FY25, a 7% increase from H1 FY24.
- Subscription revenue grew by 26% to $1.81 million.
- Rental revenue increased by 9% to $1.27 million.
- The company reported a net loss of $157,000, a 77% improvement from the previous year's loss.
- Cost optimization initiatives have significantly lowered ongoing expenses.
- Spectur is focusing on high-margin recurring revenue streams for stability and growth.
- The company transitioned to a new ERP system, reducing costs by 70%.
- Technological enhancements include improved backend software and new emergency response features.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Energy Action Limited (EAX) ORDINARY FULLY PAID |
Industrials |
$14 |
Half Year Results - Letter to Shareholders
|
27 Feb 2025 3:19PM |
$0.270 |
$0.370 |
risen by
37.04%
|
|
| Cosmo Metals Limited (CMO) ORDINARY FULLY PAID |
Materials |
$5 |
Dispatch of Entitlement Offer Prospectus
|
27 Feb 2025 3:16PM |
$0.021 |
$0.016 |
fallen by
23.81%
|
|
| Energy Action Limited (EAX) ORDINARY FULLY PAID |
Industrials |
$14 |
Half Year Results - Investor Presentation
|
27 Feb 2025 3:15PM |
$0.270 |
$0.370 |
risen by
37.04%
|
|
EAX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 7% to $5.32 million.
- Statutory profit after tax increased by 116% to $924,259.
- EBITDA improved by 33% to $1.33 million.
- Total assets decreased by 4% to $10.046 million.
- Net assets increased by 40% to $3.258 million.
- Total liabilities reduced by 16% to $6.788 million.
- Cashflow from operating activities increased by 93% to approximately $1.41 million.
- The company's technology platform, Utilibox, is evolving to better serve customer needs.
- Focus on profitable growth and positive cashflow to decrease debt continues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Summerset Group Holdings Limited (SNZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$2,467 |
Amendments to Master Trust Deed
|
27 Feb 2025 3:15PM |
$11.000 |
$10.240 |
fallen by
6.91%
|
|
| Energy Action Limited (EAX) ORDINARY FULLY PAID |
Industrials |
$14 |
Appendix 4D & Interim Financial Report
|
27 Feb 2025 3:13PM |
$0.270 |
$0.370 |
risen by
37.04%
|
|
EAX - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit after tax increased to $924,259, up 116% from the previous year.
- Total revenue declined by 7% to $5,324,156.
- Energy Management revenue increased by 6.6%, offsetting declines in other segments.
- Received a Research and Development Tax Incentive of $615,753.
- Cost reductions and operational efficiencies contributed to improved profitability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$459 |
FY25 Half Year Results Summary
|
27 Feb 2025 3:13PM |
$0.193 |
$0.160 |
fallen by
16.88%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$35 |
Appendix 4D & Half-Year Financial Statements
|
27 Feb 2025 3:13PM |
$0.155 |
$0.150 |
fallen by
3.23%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss for half-year was $1,533,422, up 32.8% from the previous year.
- Island Pharmaceuticals is focused on repurposing small molecules as antivirals.
- ISLA-101 is being advanced in a Phase 2 clinical trial for dengue fever.
- The trial is conducted in collaboration with the US Army.
- Island began recruitment for the Phase 2a/b clinical study.
- A binding Letter of Intent was executed with BioCryst for acquiring galidesivir.
- A key patent for ISLA-101 was granted by the USPTO.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wesfarmers Limited (WES) ORDINARY FULLY PAID |
Consumer Discretionary |
$95,055 |
Update - Dividend/Distribution - WES
|
27 Feb 2025 3:12PM |
$74.410 |
$83.800 |
risen by
12.62%
|
|
| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$459 |
Half Year Financial Report
|
27 Feb 2025 3:10PM |
$0.193 |
$0.160 |
fallen by
16.88%
|
|
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$38 |
Appendix 4D & Half-Year Financial Statements
|
27 Feb 2025 3:04PM |
$0.255 |
$0.170 |
fallen by
33.33%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- CYP-006TK trial completed with positive efficacy data.
- Loss for the half-year reduced to $3.65 million.
- Cash balance of $10.51 million at period end.
- Recruitment for aGvHD trial over 40% complete.
- First patient treated in kidney transplantation trial.
- Phase 3 trial for osteoarthritis completed recruitment.
- Acquisition of wound dressing technology finalized.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lynas Rare Earths Limited (LYC) ORDINARY FULLY PAID |
Materials |
$8,934 |
Lynas Rare Earths FY25 Half Year Presentation - amended
|
27 Feb 2025 3:03PM |
$6.900 |
$9.550 |
risen by
38.41%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
